Human-Based Technologies in Cardiovascular Pharmacology Research

Abstract

Human-based technologies are revolutionizing cardiovascular pharmacology by offering innovative platforms that more accurately reflect human biology and disease mechanisms than traditional animal models. These approaches include tissue chips, microphysiologic systems, engineered heart tissues, cardiac organoids, and human cardiac slices-each contributing to substantial improvements in drug testing, mechanistic understanding, and translational relevance. Complementary advances in biobanking, omics technologies, and advanced imaging offer the opportunity for multidimensional characterization of cardiovascular phenotypes, while digital health tools and wearables expand our translational armamentarium with real-time physiologic monitoring and decentralized clinical trials. Artificial intelligence and machine learning further contribute discovery pipelines by facilitating data integration and predictive modeling. The application of clustered regularly interspaced short palindromic repeats-associated protein 9 (CRISPR-Cas9) genome editing and in vitro to in vivo extrapolation frameworks underscores the growing precision and clinical orientation of these methodologies. Together, these innovations are reshaping basic research, drug development, regulatory science, and personalized medicine in cardiology. However, to fully realize their promise, challenges related to standardization, scalability, and ethical governance must be addressed. With strategic investment and cross-sector collaboration, human-based approaches are poised to lead the next generation of cardiovascular research-delivering safer, more effective therapies tailored to human-specific biology.

Keywords: artificial intelligence in drug discovery; human-based models; human-based research; in vitro to in vivo extrapolation; microphysiologic systems.